Atlas Trials

Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Clinical trial NCT05226728 · COMPLETED

Trial details

NCT number
NCT05226728
Sponsor
Sun Yat-sen University
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2018-10-10
Primary completion
2021-02-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.